What just happened? PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) stock value has climbed by nearly 7.58% or (0.4 points) to $5.68 from its previous close of $5.28. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 120765 contracts so far this session. PHAS shares had a relatively better volume day versus average trading capacity of 506.76 thousand shares, but with a 23.05 million float and a -4% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for PHAS stock indicates that the average analyst price target is $20 per share. This means the stock has a potential increase of 252.11% from where the PHAS share price has been trading recently.
During the recent trading session for PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), the company witnessed their stock rise $unch over a week and surge $1.95 from the price 20 days ago. When compared to their established 52-week high of $16.65, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 09/04/19. The recent low of $2.56 stood for a -65.89% since 12/03/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for PhaseBio Pharmaceuticals, Inc., the two-week RSI stands at 53.61. This figure suggests that PHAS stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current PHAS readings is similarly very revealing as it has a stochastic reading of 13.33% at this stage. This figure means that PHAS share price today is being overbought.
Technical chart claims that PhaseBio Pharmaceuticals, Inc. (PHAS) would settle between $5.7/share to $6.13/share level. However, if the stock price goes below the $5.03 mark, then the market for PhaseBio Pharmaceuticals, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $4.79 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.19. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at H.C. Wainwright, assumed coverage of PHAS assigning Buy rating, according to their opinion released on October 03. William Blair, analysts launched coverage of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) stock with a Outperform recommendation, according to their flash note issued to investors on September 11. Analysts at Needham, made their first call for the equity with a Buy recommendation, according to a research note that dated back to November 13.
PHAS equity has an average rating of 1.4, with the figure leaning towards a bullish end. 5 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 5 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 5 analysts rated PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
PhaseBio Pharmaceuticals, Inc. (PHAS)’s current-quarter revenues are projected to climb by nearly -2.7% to hit $250000, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 169.5% from $668000 to a noteworthy $1.8 million. At the other end of the current quarter income statement, PhaseBio Pharmaceuticals, Inc. is expected to see its adjusted earnings surge by roughly -53.8% to hit $-0.4 per share. For the fiscal year, PHAS’s earnings are projected to climb by roughly 68.2% to hit $-1.43 per share.